Shengli Lab

Home Team Publications Resources

Shengli Li received his Ph.D. in Medical Systems Biology from Fudan University in 2018 and Postdoctoral training from the University of Texas Health Science center at Houston during 2018-2020. He is a Principal Investigator with the Shanghai General Hospital affiliated to Shanghai Jiao Tong University. Shengli is a computational biologist with expertise in human disease genetics, including cancer and skin diseases. His research focuses on integrative utilization of cutting-edge computational biology algorithms and molecular experimental technologies to reveal systematical changes and functional factors in human disease progression, disease microenvironment and response to drug treatment.


Research Interests

We are dedicated to solving critical questions in human disease biology by using cutting-edge bioinformatics and genomics technologies, especially cancer. Specially, we integrate computational biology algorithms and molecular experimental technologies to reveal systematical changes and functional factors in disease progression, disease microenvironment and response to drug treatment. Our studies are aiming to impel the development of immunotherapy and targeted therapy. First, we use single-cell sequencing technology to study disease microenvironment, especially the accurate compositions and functions of infiltrated immune cells. Single-cell sequencing is also used to study disease heterogeneity and its impact on disease cell functions and drug sensitivity. Second, we utilize bioinformatics methods to analyze disease multi-omics data, revealing disease subtypes, driver genes and hereditary basis of other pathogens, such as gene fusion, alterations of alleles and disease-specific isoforms. Our study discovers candidate targets for disease diagnosis and therapy. Third, we develop original bioinformatics tools for analysis, integration and visualization of single-cell and other high-throughput disease omics data. We expect to promote the development of disease immunotherapy and targeted therapy through immunogenomics.
News

2023-02-02 : Shengli's paper is accepted in Nature Communications!
2021-12-02 : Teng's paper is accepted in Clinical and Translational Discovery!
2021-11-04 : Wei's collaborative paper is accepted in Molecular Therapy - Nucleic Acids!
2021-10-16 : Jingni's Review paper is accepted in Frontiers in Immunology!
2021-06-27 : Wei and Zhixiao's collaborative paper is accepted in Molecular Therapy - Nucleic Acids!
2021-06-07 : Zhixiao's Spotlight paper is accepted in Trends in Genetics!
2021-04-30 : Yangjun's Spotlight paper is accepted in Trends in Cancer!
2021-04-21 : Shengli was invited to be the Associate Editor of Frontiers in Bioinformatics in Drug Discovery in Bioinformatics section!
2021-03-29 : Our collaborative paper is accepted in Molecular Therapy-Nucleic Acids!
2021-02-18 : Shengli was invited to be the Guest Editor of Special Issue "Bioinformatics and Machine Learning for Cancer Biology" in Biology!
2021-02-03 : Zhixiao's review paper is published in Frontiers in Immunology!
2021-01-28 : Wei's paper is accepted in Frontiers in Cell and Developmental Biology!
2021-01-27 : Our collaborative paper is accepted in STAR Protocols!
2020-10-08 : Shengli Lab is established in Shanghai General Hospital affiliated to Shanghai Jiao Tong University!